UNSPSC 51142516: Tolcapone

This classification denotes an antiparkinsonian agent with the molecular formula C14H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CIF6334OLY, chemically known as 3,4-dihydroxy-4-methyl-5-nitrobenzophenone but generally known as tolcapone, which bears US NIH Compound Identifier 4659569. European Medicines Agency schedules Tolcapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11151MIG.

UNSPSC 51142516 Tolcapone is a Commodity code that nominally represents a single pharmaceutical product; however, the recent state and local opportunities tagged under this code show substantial mismatch with tolcapone specifically. Instead, the opportunities describe broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. State and local governments are using this code to solicit pharmaceutical supply agreements, often through centralized cooperative purchasing vehicles or county health departments, where the actual work involves vendor qualification, product compliance certification, pricing negotiation across multiple therapeutic categories, and logistics coordination for quarterly or ongoing delivery to healthcare facilities and county health buildings. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP). The code shows low signal specificity for tolcapone as a distinct product line and should be treated as a proxy for broader pharmaceutical procurement activity rather than a dedicated category.

Recent activity spans Florida, Texas, and Minnesota, with the most detailed opportunities showing vendor qualification requirements, insurance mandates, and compliance frameworks typical of state pharmaceutical contracting. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the posted date is June 2026 but the due date is retroactively July 2023, indicating a data quality issue in the source). The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a therapeutic pharmacy initiative direct-to-manufacturer prescriptions program. The Minnesota Department of Administration, administering MMCAP, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across multiple states including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors typically face 3 percent administrative fees, cGMP and DSCSA compliance requirements, and performance penalties for reporting or onboarding delays.